• Explore /
  • Poster
  • / Validation of the ELN-2017 risk classification in younger adult patients (pts) with AML.

Validation of the ELN-2017 risk classification in younger adult patients (pts) with AML.

Abstract Poster

Authors

null

Prajwal Boddu

The University of Texas MD Anderson Cancer Center, Houston, TX

Prajwal Boddu , Tapan M. Kadia , Guillermo Garcia-Manero , Jorge E. Cortes , Gautam Borthakur , Marina Konopleva , Elias Jabbour , Naval Guastad Daver , Courtney Denton Dinardo , Kiran Naqvi , Musa Yilmaz , Nicholas James Short , Graciela M. Nogueras-Gonzalez , Sherry Pierce , Hagop M. Kantarjian , Farhad Ravandi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Citation

J Clin Oncol 36, 2018 (suppl; abstr 7053)

DOI

10.1200/JCO.2018.36.15_suppl.7053

Abstract #

7053

Poster Bd #

113

Abstract Disclosures

Similar Posters

Poster

2020 ASCO Virtual Scientific Program

Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS.

Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS.

First Author: Abhishek Maiti

First Author: Suravi Raychaudhuri

First Author: Somedeb Ball

First Author: Jeffrey E. Lancet